| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 01/15/2003 | CN1391573A Bicyclic imidazo-3-yl-amine derivatives |
| 01/15/2003 | CN1391571A Heterocyclic compounds and their use as medicines |
| 01/15/2003 | CN1391570A Phenyl-and pyridyl-tetrahydro-pyridines having TNF inhibiting activity |
| 01/15/2003 | CN1391564A Chemical compounds |
| 01/15/2003 | CN1391556A IL-8 receptor antagonists |
| 01/15/2003 | CN1391479A Medicament for inducing tolerance |
| 01/15/2003 | CN1391475A Optically active isomers of ketotifen and therapeutically active metabolites thereof |
| 01/15/2003 | CN1391474A 5-membered heterocycle derivatives, production thereof and use as medicaments |
| 01/15/2003 | CN1391473A VLA-4 inhibitor compounds |
| 01/15/2003 | CN1391470A Pharmaceutical composition and method for treatment of inflammation |
| 01/15/2003 | CN1391464A Formulation for menopausal women |
| 01/15/2003 | CN1390837A Anti-inflammatory and antineoplastic R-bis or glycophenylpropane isoselenazole substituted compound |
| 01/15/2003 | CN1390605A Medicine C-AEDP using C as carrier for target therapy of osteopath and its usage |
| 01/15/2003 | CN1390603A Applicaltion of buthotoxin Bmk AS in preparing medicines |
| 01/15/2003 | CN1390596A Mayi-shuangshen Tongbi pill for treating rheumatoid or rheumatic arthitis and ankylosing spondylitis |
| 01/15/2003 | CN1390589A Quick-acting antalgesic-antipruritic tincture |
| 01/15/2003 | CN1390582A Crude drugs pastes |
| 01/15/2003 | CN1390577A Pill of tortoise plastron and turtle shell |
| 01/15/2003 | CN1390568A Capsule fr promoting blood circulation and removing obstruction in channel |
| 01/15/2003 | CN1390565A Process for preparing product containing antiinflammatory, anticoagulant and antibacterial components from ginger and its product and medical composition |
| 01/15/2003 | CN1390554A Inflammation relieving paste |
| 01/15/2003 | CN1390553A Liquid defervescent |
| 01/15/2003 | CN1098689C Pharmaceutical composition for treating stomaperipheral inflammation diseases |
| 01/14/2003 | US6506912 Method of locking 1α-OH of vitamin D compounds in axial orientation |
| 01/14/2003 | US6506876 LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use |
| 01/14/2003 | US6506799 Treating or preventing a cardiovascular disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of 6-(6-hydroxy-5,5-dimethylhexyloxy)-2,2-dimethyl-hexan-1-ol and |
| 01/14/2003 | US6506796 Cosmetically or therapeutically treating diseases or disorders in cell populations whose pathology is linked to an inadequate rate of apoptosis by administering a therapeutically effective amount of |
| 01/14/2003 | US6506779 Acetylene derivatives as anti-inflammatory/analgesic agents |
| 01/14/2003 | US6506775 Substituted benzylaminopiperidine compounds |
| 01/14/2003 | US6506773 Hydroxamic and carboxylic acid derivatives |
| 01/14/2003 | US6506766 Glucocortiocoid-selective antinflammatory agents |
| 01/14/2003 | US6506764 Hydroxamic and carboxylic acid derivatives |
| 01/14/2003 | US6506762 Certain alkylene diamine-substituted heterocycles |
| 01/14/2003 | US6506756 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 01/14/2003 | US6506750 Morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives |
| 01/14/2003 | US6506748 Aromatic heterocyclic compounds as antiinflammatory agents |
| 01/14/2003 | US6506747 Method of treating an inflammatory disease which comprises administering to a patient in need of such treatment-a N-(4-(5-Ethyl-3-pyridin-3-yl-pyrazol-1-yl)phenyl)pyridine-3-carboxamide; |
| 01/14/2003 | US6506740 Compounds that can be substituted at the 7, 8, and/or 9 positions and methods for preparing the 4- dedimethylamino tetracycline compounds. Other tetracycline compounds are the 4-dedimethylaminotetracycline derivatives with an oxime |
| 01/14/2003 | US6506582 Extended by aspartic acid at 5' end and shortened at 3' end by one to eight amino acids; nonimmunogenic; binds CD4 lymphocytes |
| 01/14/2003 | US6506555 Use of HIV protease inhibiting compounds |
| 01/14/2003 | US6506383 Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies |
| 01/14/2003 | CA2114313C Bpc peptides, their preparation and use |
| 01/14/2003 | CA2067975C Buffered matrix aspirin tablet |
| 01/09/2003 | WO2003003004A2 Method for identifying compounds the specifically deplete mast cells |
| 01/09/2003 | WO2003002713A2 Antibodies to opgl |
| 01/09/2003 | WO2003002610A1 Extracellular messengers |
| 01/09/2003 | WO2003002607A1 Reducing immunogenicities of immunoglobulins by framework-patching |
| 01/09/2003 | WO2003002600A1 Use of soluble cytokeratine-1-fragments in diagnostics and therapy |
| 01/09/2003 | WO2003002568A1 Carbohydrate derivatives |
| 01/09/2003 | WO2003002554A1 Piperazine compounds |
| 01/09/2003 | WO2003002553A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002544A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | WO2003002542A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | WO2003002540A1 Cyclic diamine compound having five-membered cyclic group |
| 01/09/2003 | WO2003002539A1 Dibenzocycloheptene compound |
| 01/09/2003 | WO2003002537A1 Bis(5-aryl-2-pyridyl) derivative |
| 01/09/2003 | WO2003002535A1 Cyclic diamine compounds bearing six-membered cyclic groups |
| 01/09/2003 | WO2003002532A1 Cyclic diamine compounds having fused-ring groups |
| 01/09/2003 | WO2003002531A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002530A2 Pyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002524A2 Urea derivatives with antiproteolytic activity |
| 01/09/2003 | WO2003002511A1 Cycloalkenone derivative |
| 01/09/2003 | WO2003002503A1 Thienothiazine compounds having anti-inflammatory and analgesic activities and their preparation methods and the use there of |
| 01/09/2003 | WO2003002149A2 Use of pigment such as e.g. titanium dioxide for obtaining a special optical effect on oral medicament or food |
| 01/09/2003 | WO2003002144A1 Bispecific antibodies that bind to vegf receptors |
| 01/09/2003 | WO2003002129A1 Use of sulodexide for the treatment of inflammatory bowel disease |
| 01/09/2003 | WO2003002118A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | WO2003002109A2 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | WO2003002108A2 Use of tyrosine kinase inhibitors for treating inflammatory diseases |
| 01/09/2003 | WO2003002102A1 Sustained release pharmaceutical composition |
| 01/09/2003 | WO2003002093A1 Olopatadine formulations for topical administration |
| 01/09/2003 | WO2003002058A2 Bone anabolic compounds and methods of use |
| 01/09/2003 | WO2002080976A3 Hsa-free formulations of interferon-beta |
| 01/09/2003 | WO2002072536A8 Urea derivatives having vanilloid receptor (vr1) antagonist activity |
| 01/09/2003 | WO2002071874A3 Composition improving age-related physiological deficits and increasing longevity |
| 01/09/2003 | WO2002064594A3 6-substituted pyrido-pyrimidines |
| 01/09/2003 | WO2002059111A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/09/2003 | WO2002059102A3 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use |
| 01/09/2003 | WO2002057231A3 Benz(g) indoles and their use as spla2 inhibitors |
| 01/09/2003 | WO2002046423A3 Protein derived from the melanin-concentrating hormone (mch), corresponding nucleic acids and their use for preparing medicines |
| 01/09/2003 | WO2002046373A9 Method of collecting placental stem cells |
| 01/09/2003 | WO2002044320A3 Human elongase genes and uses thereof |
| 01/09/2003 | WO2002036625A3 Prokineticin polypeptides, related compositions and methods |
| 01/09/2003 | WO2002034236A3 Lipid formulations for target delivery |
| 01/09/2003 | WO2002032953A3 Pregnancy-associated plasma protein-a2 (papp-a2) |
| 01/09/2003 | WO2002031142A3 Antisense nucleic acid against alphav integrin |
| 01/09/2003 | WO2002000017A3 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/09/2003 | WO2001081369A3 Peptide potentiation of acid-sensory ion channel in pain |
| 01/09/2003 | WO2001079480A9 Albumin fusion proteins |
| 01/09/2003 | WO2001072728B1 Novel piperazine derivatives |
| 01/09/2003 | WO2001062238A9 Ppar gamma agonists for the treatment of liver inflammatory disorders |
| 01/09/2003 | WO2001057267A9 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 01/09/2003 | WO2001056532A9 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
| 01/09/2003 | WO2001055336A9 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/09/2003 | WO2001055333A9 Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides |
| 01/09/2003 | US20030008908 Isoxazoline compounds having MIF antagonist activity |
| 01/09/2003 | US20030008906 Administering benzothiazole compound for therapy, prophylaxis of disease |
| 01/09/2003 | US20030008905 Increasing the capacity of insulin providing cells in an animal by administering to animal a dose of at least one Dipeptidyl-peptidase (DP IV) enzyme activity effector |
| 01/09/2003 | US20030008893 For prophylaxis and therapy of diseases associated with monocyte accumulation, lymphocyte accumulation or leucocyte accumulation |
| 01/09/2003 | US20030008886 For therapy of pain |